Analyst Research

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: Stock Traders Daily
$20.00
Provider: New Constructs, LLC
$25.00
Provider: MacroRisk Analytics/EconomicInvestor
$25.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

West Pharmaceutical Services Inc Issues FY 2013 Guidance; Revenue Guidance Above Analysts' Estimates


Thursday, 21 Feb 2013 07:14am EST 

West Pharmaceutical Services Inc announced that for fiscal 2013, it expects consolidated net sales in the range of $1.360-$1.400 billion, diluted earnings per share in the range of $3.00-$3.20 and adjusted diluted EPS (adjusted diluted EPS is a Non-GAAP measurement) in the range of $2.97-$3.17. The Company's estimated guidance for fiscal 2013 includes $12 million of expected sales and development income and between $0.11-$0.15 of adjusted diluted EPS, that are associated with customers' research and pre-commercial work with Daikyo Crystal Zenith and other administration devices, the nature of which increases the risk that actual results may be lower than estimates. According to I/B/E/S Estimates, analysts were expecting the Company to report revenue of $1.317 billion and EPS of $3.00 for fiscal 2013. 

Company Quote

52.11
0.17 +0.33%
26 Nov 2014